Search

everythinglearnresearchcommunity

for

Search:↓

Using mirabegron and solifenacin together is safe and more effective for treating overactive bladder than using either drug alone.

Baricitinib and tofacitinib have different safety patterns in treating alopecia areata.

Vorasidenib can cause unusual hair growth.

The topical inhibitor CUR61414 was not effective in treating basal cell carcinoma in human trials.

Tofacitinib helped a woman regrow hair with no major side effects.

Baricitinib improved hair loss and arthritis in a lupus patient.

Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.

Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.

Busulfan/cyclophosphamide and total bone irradiation are equally effective for AML transplants.

Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.

Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.

Doctors should actively prevent and treat skin side effects in cancer patients to keep them on the best medication and reduce discomfort.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.

Upadacitinib improved multiple immune-related conditions in one patient.

Most pediatric cancer patients at Muhimbili National Hospital experienced adverse drug reactions during chemotherapy, highlighting the need for careful monitoring.

Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.

Fesoterodine is effective and safe for elderly patients with overactive bladder.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.

Filgotinib completely reversed hair loss in a patient with rheumatoid arthritis and alopecia universalis.

Adverse events in lung cancer treatments increase fear, anxiety, and depression, with newer therapies causing fewer side effects.

The patient showed tumor stability and improved health using a new Periwinkle preparation with chemotherapy.

A scalp-cooling system effectively prevents hair loss in breast cancer patients treated with eribulin.

Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.